Published in Exp Neurol on September 09, 2010
MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein. Hum Mol Genet (2012) 1.11
Atp13a2 expression in the periaqueductal gray is decreased in the Pink1 -/- rat model of Parkinson disease. Neurosci Lett (2016) 1.08
Open conformation of human DOPA decarboxylase reveals the mechanism of PLP addition to Group II decarboxylases. Proc Natl Acad Sci U S A (2011) 0.98
Gene expression profiles in Parkinson disease prefrontal cortex implicate FOXO1 and genes under its transcriptional regulation. PLoS Genet (2012) 0.94
Age-related changes in rostral basal forebrain cholinergic and GABAergic projection neurons: relationship with spatial impairment. Neurobiol Aging (2012) 0.88
Follow-up study of abnormal biological indicators and gene expression in the peripheral blood of three accidentally exposed persons. J Radiat Res (2013) 0.79
Neuropsychological, Neurovirological and Neuroimmune Aspects of Abnormal GABAergic Transmission in HIV Infection. J Neuroimmune Pharmacol (2016) 0.78
Structural characterization of the mechanism through which human glutamic acid decarboxylase auto-activates. Biosci Rep (2013) 0.77
MicroRNAs in Parkinson's disease. Exp Brain Res (2017) 0.76
Decreased parvalbumin mRNA expression in dorsolateral prefrontal cortex in Parkinson's disease. Brain Res (2013) 0.75
Executive function deficits and glutamatergic protein alterations in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. J Neurosci Res (2015) 0.75
Integrative analyses of proteomics and RNA transcriptomics implicate mitochondrial processes, protein folding pathways and GWAS loci in Parkinson disease. BMC Med Genomics (2016) 0.75
Gad67 haploinsufficiency reduces amyloid pathology and rescues olfactory memory deficits in a mouse model of Alzheimer's disease. Mol Neurodegener (2017) 0.75
Detection of mrnas in sea urchin embryos by in situ hybridization using asymmetric RNA probes. Dev Biol (1984) 12.47
Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci (2005) 11.68
Cellular basis of working memory. Neuron (1995) 8.22
The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APMIS (1988) 6.75
Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci (2008) 5.12
GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology (2001) 4.41
Two genes encode distinct glutamate decarboxylases. Neuron (1991) 3.68
Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease. Neurosci Biobehav Rev (2005) 3.60
Cleft palate and decreased brain gamma-aminobutyric acid in mice lacking the 67-kDa isoform of glutamic acid decarboxylase. Proc Natl Acad Sci U S A (1997) 2.91
Cognitive deficits in Parkinson's disease. J Neurol (1997) 2.49
Functional and pathophysiological models of the basal ganglia. Curr Opin Neurobiol (1996) 2.45
Two isoforms of glutamate decarboxylase: why? Trends Pharmacol Sci (1998) 2.40
The role of the mid-dorsolateral prefrontal cortex in working memory. Exp Brain Res (2000) 2.39
The relative importance of premortem acidosis and postmortem interval for human brain gene expression studies: selective mRNA vulnerability and comparison with their encoded proteins. Neurosci Lett (1995) 2.35
Comparative localization of two forms of glutamic acid decarboxylase and their mRNAs in rat brain supports the concept of functional differences between the forms. J Neurosci (1994) 2.24
Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry. J Neurosci (2003) 2.22
Changes in excitability of motor cortical circuitry in patients with Parkinson's disease. Ann Neurol (1995) 2.03
Basal-ganglia 'projections' to the prefrontal cortex of the primate. Cereb Cortex (2002) 1.98
Tissue pH as an indicator of mRNA preservation in human post-mortem brain. Brain Res Mol Brain Res (1995) 1.98
Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J Neurol Sci (1977) 1.83
GABAergic neurons immunoreactive for calcium binding proteins are reduced in the prefrontal cortex in major depression. Neuropsychopharmacology (2006) 1.80
Cognitive function in Parkinson's disease: from description to theory. Trends Neurosci (1990) 1.76
Complex I deficiency in Parkinson's disease frontal cortex. Brain Res (2007) 1.61
Pathological substrate of dementia in Parkinson's disease--its relation to DLB and DLBD. Parkinsonism Relat Disord (2005) 1.54
Mechanisms of dopamine activation of fast-spiking interneurons that exert inhibition in rat prefrontal cortex. J Neurophysiol (2002) 1.54
Synapses are lost during aging in the primate prefrontal cortex. Neuroscience (2007) 1.50
Functional networks in motor sequence learning: abnormal topographies in Parkinson's disease. Hum Brain Mapp (2001) 1.48
Cognitive deficits and striato-frontal dopamine release in Parkinson's disease. Brain (2008) 1.45
Different distributions of GAD65 and GAD67 mRNAs suggest that the two glutamate decarboxylases play distinctive functional roles. J Neurosci Res (1993) 1.42
Brain pH has a significant impact on human postmortem hippocampal gene expression profiles. Brain Res (2006) 1.31
A critical reappraisal of current staging of Lewy-related pathology in human brain. Acta Neuropathol (2008) 1.29
The distribution of tyrosine hydroxylase-immunoreactive fibers in primate neocortex is widespread but regionally specific. J Neurosci (1987) 1.29
Learning networks in health and Parkinson's disease: reproducibility and treatment effects. Hum Brain Mapp (2003) 1.23
Regional and laminar distribution of the dopamine and serotonin innervation in the macaque cerebral cortex: a radioautographic study. J Comp Neurol (1988) 1.22
Pattern of brain destruction in Parkinson's and Alzheimer's diseases. J Neural Transm (Vienna) (1996) 1.20
Deep brain stimulation for Parkinson's disease dissociates mood and motor circuits: a functional MRI case study. Mov Disord (2003) 1.19
Dopamine increases inhibition in the monkey dorsolateral prefrontal cortex through cell type-specific modulation of interneurons. Cereb Cortex (2006) 1.17
Alterations of dopaminergic and noradrenergic innervations in motor cortex in Parkinson's disease. Ann Neurol (1991) 1.17
Motor cortex dysfunction revealed by cortical excitability studies in Parkinson's disease: influence of antiparkinsonian treatment and cortical stimulation. Clin Neurophysiol (2004) 1.14
Selective modulation of excitatory and inhibitory microcircuits by dopamine. Proc Natl Acad Sci U S A (2003) 1.13
Endogenous dopamine release after pharmacological challenges in Parkinson's disease. Ann Neurol (2003) 1.10
Imaging in Parkinson's disease: the role of monoamines in behavior. Biol Psychiatry (2006) 1.08
Dopamine modulation of membrane and synaptic properties of interneurons in rat cerebral cortex. J Neurophysiol (1999) 1.07
Neural correlates of STN DBS-induced cognitive variability in Parkinson disease. Neuropsychologia (2008) 1.03
Prefrontal neurons in networks of executive memory. Brain Res Bull (2000) 1.02
Alteration in alpha-synuclein mRNA expression in Parkinson's disease. Mov Disord (2004) 1.01
Abnormal excitability of premotor-motor connections in de novo Parkinson's disease. Brain (2004) 1.01
Early involvement of the cerebral cortex in Parkinson's disease: convergence of multiple metabolic defects. Prog Neurobiol (2009) 1.01
Quality of life measurements in patients with Parkinson's disease: A community-based study. Eur J Neurol (1998) 0.99
Stability of RNA transcripts in post-mortem psychiatric brains. J Neural Transm (Vienna) (1999) 0.99
Effect of apomorphine on cortical inhibition in Parkinson's disease patients: a transcranial magnetic stimulation study. Exp Brain Res (2001) 0.97
Age-related changes in GAD levels in the central auditory system of the rat. Exp Gerontol (2008) 0.96
Differential localization of two glutamic acid decarboxylases (GAD65 and GAD67) in adult monkey visual cortex. J Comp Neurol (1994) 0.94
The dopaminergic innervation of monkey prefrontal cortex: a tyrosine hydroxylase immunohistochemical study. Brain Res (1988) 0.94
Changes in regional cerebral blood flow caused by deep-brain stimulation of the subthalamic nucleus in Parkinson's disease. J Nucl Med (2002) 0.92
Hypoperfusion in the supplementary motor area, dorsolateral prefrontal cortex and insular cortex in Parkinson's disease. J Neurol Sci (2001) 0.91
Region-specific distribution of catecholamine afferents in primate cerebral cortex: a fluorescence histochemical analysis. J Comp Neurol (1984) 0.89
A post mortem study on neurochemical markers of dopaminergic, GABA-ergic and glutamatergic neurons in basal ganglia-thalamocortical circuits in Parkinson syndrome. Brain Res (1996) 0.88
Increased glutamate decarboxylase mRNA levels in the striatum and pallidum of MPTP-treated primates. J Neurosci (1994) 0.88
In situ hybridization demonstrates the stability of mRNA in post-mortem rat tissues. J Pathol (1992) 0.86
Brain glutamate decarboxylase in Parkinson's disease with particular reference to a premortem severity index. Brain (1985) 0.86
GABAA receptor but not muscarinic receptor density was decreased in the brain of patients with Parkinson's disease. Jpn J Pharmacol (1988) 0.86
Glutamate decarboxylase-67 messenger RNA expression in normal human basal ganglia and in Parkinson's disease. Neuroscience (1996) 0.83
Consequence of nigrostriatal denervation and L-dopa therapy on the expression of glutamic acid decarboxylase messenger RNA in the pallidum. Neurology (1996) 0.82
No global loss of neocortical neurons in Parkinson's disease: a quantitative stereological study. Mov Disord (2005) 0.79
Alterations in prodynorphin, proenkephalin, and GAD67 mRNA levels in the aged human putamen: correlation with Parkinson's disease. J Neurosci Res (2007) 0.79
Post-mortem degradation of brain glutamate decarboxylase. Neurochem Int (2003) 0.77
Effects of nigrostriatal denervation and L-dopa therapy on the GABAergic neurons in the striatum in MPTP-treated monkeys and Parkinson's disease: an in situ hybridization study of GAD67 mRNA. Eur J Neurosci (1995) 0.77
Regional differences in the changes in rat brain GABA concentrations post mortem and following inhibition of the synthesis and metabolism. Pharmacol Toxicol (1987) 0.76
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell (2011) 6.56
Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet (2008) 5.04
Retracted Genetic signatures of exceptional longevity in humans. Science (2010) 4.33
Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. PLoS Genet (2012) 4.27
A genome-wide association study of pulmonary function measures in the Framingham Heart Study. PLoS Genet (2009) 3.78
Genetic signatures of exceptional longevity in humans. PLoS One (2012) 3.20
Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. Ann Neurol (2012) 2.20
The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study. BMC Med (2008) 2.10
A genome-wide scan for loci linked to plasma levels of glucose and HbA(1c) in a community-based sample of Caucasian pedigrees: The Framingham Offspring Study. Diabetes (2002) 1.99
HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum Mol Genet (2005) 1.96
Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study. Arch Neurol (2006) 1.94
A genome scan for modifiers of age at onset in Huntington disease: The HD MAPS study. Am J Hum Genet (2003) 1.85
Decreased GAD67 mRNA levels in cerebellar Purkinje cells in autism: pathophysiological implications. Acta Neuropathol (2007) 1.71
Quantitative-trait loci influencing body-mass index reside on chromosomes 7 and 13: the National Heart, Lung, and Blood Institute Family Heart Study. Am J Hum Genet (2001) 1.59
Somatic expansion of the Huntington's disease CAG repeat in the brain is associated with an earlier age of disease onset. Hum Mol Genet (2009) 1.51
Genome-wide association studies identify CHRNA5/3 and HTR4 in the development of airflow obstruction. Am J Respir Crit Care Med (2012) 1.49
Genetic loci influencing lung function: a genome-wide scan in the Framingham Study. Am J Respir Crit Care Med (2002) 1.47
Linkage of the cholesterol 7alpha-hydroxylase gene and low-density lipoprotein cholesterol conditional on apolipoprotein E association: the National Heart, Lung, and Blood Institute Family Heart Study. Chin Med J (Engl) (2005) 1.42
Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: the GenePD study. Mov Disord (2008) 1.41
Genomewide linkage analysis to presbycusis in the Framingham Heart Study. Arch Otolaryngol Head Neck Surg (2003) 1.38
Genetic variability of adult body mass index: a longitudinal assessment in framingham families. Obes Res (2002) 1.34
High-dose methamphetamine acutely activates the striatonigral pathway to increase striatal glutamate and mediate long-term dopamine toxicity. J Neurosci (2004) 1.33
Retraction. Science (2011) 1.32
Genetic background modifies nuclear mutant huntingtin accumulation and HD CAG repeat instability in Huntington's disease knock-in mice. Hum Mol Genet (2006) 1.32
Genome-wide significance for a modifier of age at neurological onset in Huntington's disease at 6q23-24: the HD MAPS study. BMC Med Genet (2006) 1.30
Fosmids of novel marine Planctomycetes from the Namibian and Oregon coast upwelling systems and their cross-comparison with planctomycete genomes. ISME J (2007) 1.26
Considerations for genomewide association studies in Parkinson disease. Am J Hum Genet (2006) 1.26
The relationship between CAG repeat length and age of onset differs for Huntington's disease patients with juvenile onset or adult onset. Ann Hum Genet (2006) 1.26
Linkage analysis of a composite factor for the multiple metabolic syndrome: the National Heart, Lung, and Blood Institute Family Heart Study. Diabetes (2003) 1.24
Genomewide association study for onset age in Parkinson disease. BMC Med Genet (2009) 1.24
The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. J Neuropathol Exp Neurol (2007) 1.21
PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study. Am J Hum Genet (2002) 1.19
A genome-wide scan of pulmonary function measures in the National Heart, Lung, and Blood Institute Family Heart Study. Am J Respir Crit Care Med (2003) 1.19
Evidence for a modifier of onset age in Huntington disease linked to the HD gene in 4p16. Neurogenetics (2004) 1.19
Serum iron levels and the risk of Parkinson disease: a Mendelian randomization study. PLoS Med (2013) 1.18
Linkage and association with pulmonary function measures on chromosome 6q27 in the Framingham Heart Study. Hum Mol Genet (2003) 1.14
Increased GAD67 mRNA expression in cerebellar interneurons in autism: implications for Purkinje cell dysfunction. J Neurosci Res (2008) 1.11
Genetic effect on blood pressure is modulated by age: the Hypertension Genetic Epidemiology Network Study. Hypertension (2008) 1.10
LRRK2 is not a significant cause of Parkinson's disease in French-Canadians. Can J Neurol Sci (2007) 1.09
Longitudinal and age trends of metabolic syndrome and its risk factors: the Family Heart Study. Nutr Metab (Lond) (2006) 1.08
Human-specific histone methylation signatures at transcription start sites in prefrontal neurons. PLoS Biol (2012) 1.08
Common SNP-based haplotype analysis of the 4p16.3 Huntington disease gene region. Am J Hum Genet (2012) 1.05
A genome-wide scan for loci affecting normal adult height in the Framingham Heart Study. Hum Hered (2003) 1.04
Estimating the probability of de novo HD cases from transmissions of expanded penetrant CAG alleles in the Huntington disease gene from male carriers of high normal alleles (27-35 CAG). Am J Med Genet A (2009) 1.03
Copy number variation in familial Parkinson disease. PLoS One (2011) 1.02
Assessment of cortical and striatal involvement in 523 Huntington disease brains. Neurology (2012) 1.00
HaploBuild: an algorithm to construct non-contiguous associated haplotypes in family based genetic studies. Bioinformatics (2007) 0.98
An evaluation of the metabolic syndrome in the HyperGEN study. Nutr Metab (Lond) (2005) 0.97
Circulating soluble ICAM-1 levels shows linkage to ICAM gene cluster region on chromosome 19: the NHLBI Family Heart Study follow-up examination. Atherosclerosis (2007) 0.97
State of the art review: molecular diagnosis of inherited movement disorders. Movement Disorders Society task force on molecular diagnosis. Mov Disord (2003) 0.96
Influence of apolipoprotein E, smoking, and alcohol intake on carotid atherosclerosis: National Heart, Lung, and Blood Institute Family Heart Study. Stroke (2002) 0.96
Brain-derived neurotrophic factor does not influence age at neurologic onset of Huntington's disease. Neurobiol Dis (2006) 0.95
Leptin is associated with blood pressure and hypertension in women from the National Heart, Lung, and Blood Institute Family Heart Study. Hypertension (2009) 0.94
Gene expression profiles in Parkinson disease prefrontal cortex implicate FOXO1 and genes under its transcriptional regulation. PLoS Genet (2012) 0.94
Cyclin-G-associated kinase modifies α-synuclein expression levels and toxicity in Parkinson's disease: results from the GenePD Study. Hum Mol Genet (2011) 0.91
Replication of association between ELAVL4 and Parkinson disease: the GenePD study. Hum Genet (2008) 0.91
A genome-wide screen reveals evidence for a locus on chromosome 11 influencing variation in LDL cholesterol in the NHLBI Family Heart Study. Hum Genet (2002) 0.91
Quantitative trait loci for metabolic syndrome in the Hypertension Genetic Epidemiology Network study. Obes Res (2005) 0.89
Evaluation of Parkinson disease risk variants as expression-QTLs. PLoS One (2012) 0.88
Sepiapterin reductase expression is increased in Parkinson's disease brain tissue. Brain Res (2007) 0.86
Is DFNA5 a susceptibility gene for age-related hearing impairment? Eur J Hum Genet (2002) 0.86
The etiopathogenesis of Parkinson disease and suggestions for future research. Part II. J Neuropathol Exp Neurol (2007) 0.86
Genome-wide admixture mapping for coronary artery calcification in African Americans: the NHLBI Family Heart Study. Genet Epidemiol (2008) 0.85
Polymorphisms near EXOC4 and LRGUK on chromosome 7q32 are associated with Type 2 Diabetes and fasting glucose; the NHLBI Family Heart Study. BMC Med Genet (2008) 0.85
Evidence for a gene influencing heart rate on chromosome 5p13-14 in a meta-analysis of genome-wide scans from the NHLBI Family Blood Pressure Program. BMC Med Genet (2006) 0.85
Evidence for a gene influencing heart rate on chromosome 4 among hypertensives. Hum Genet (2002) 0.84
Multiple genes influence BMI on chromosome 7q31-34: the NHLBI Family Heart Study. Obesity (Silver Spring) (2009) 0.84
LIPC variants in the promoter and intron 1 modify HDL-C levels in a sex-specific fashion. Atherosclerosis (2008) 0.84
Genetic analysis of the GRIK2 modifier effect in Huntington's disease. BMC Neurosci (2006) 0.84
Postmortem Interval Influences α-Synuclein Expression in Parkinson Disease Brain. Parkinsons Dis (2012) 0.83
Genotype-by-sex interaction on fasting insulin concentration: the HyperGEN study. Diabetes (2007) 0.83
Population stratification may bias analysis of PGC-1α as a modifier of age at Huntington disease motor onset. Hum Genet (2012) 0.83
Linkage analysis of diabetes status among hypertensive families: the Hypertension Genetic Epidemiology Network study. Diabetes (2004) 0.82
Genomewide linkage study of modifiers of LRRK2-related Parkinson's disease. Mov Disord (2011) 0.82
Haloperidol treatment after high-dose methamphetamine administration is excitotoxic to GABA cells in the substantia nigra pars reticulata. J Neurosci (2007) 0.81
Genome-wide linkage analyses for age at diagnosis of hypertension and early-onset hypertension in the HyperGEN study. Am J Hypertens (2004) 0.81
Estrogen-related and other disease diagnoses preceding Parkinson's disease. Clin Epidemiol (2010) 0.81
Evidence of QTL on 15q21 for high-density lipoprotein cholesterol: the National Heart, Lung, and Blood Institute Family Heart Study (NHLBI FHS). Atherosclerosis (2006) 0.81
TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease. Biochem Biophys Res Commun (2012) 0.81
A QTL on 12q influencing an inflammation marker and obesity in white women: the NHLBI Family Heart Study. Obesity (Silver Spring) (2008) 0.79
Risk of Parkinson's disease after tamoxifen treatment. BMC Neurol (2010) 0.79
Apolipoprotein E polymorphism modifies the alcohol-HDL association observed in the National Heart, Lung, and Blood Institute Family Heart Study. Am J Clin Nutr (2004) 0.78
The analysis of survival data with a non-susceptible fraction and dual censoring mechanisms. Stat Med (2003) 0.78
Monozygotic twins discordant for Huntington disease after 7 years. Arch Neurol (2005) 0.78
Dual effects of intermittent or continuous L-DOPA administration on gene expression in the globus pallidus and subthalamic nucleus of adult rats with a unilateral 6-OHDA lesion. Synapse (2003) 0.77
Genome-wide scan identifies novel QTLs for cholesterol and LDL levels in F2[Dahl RxS]-intercross rats. Circ Res (2004) 0.77
Evidence for three novel QTLs for adiposity on chromosome 2 with epistatic interactions: the NHLBI Family Heart Study. Obesity (Silver Spring) (2009) 0.77
Candidate glutamatergic and dopaminergic pathway gene variants do not influence Huntington's disease motor onset. Neurogenetics (2013) 0.77
Feasibility of Huntington disease trials in the disease prodrome. Neurology (2014) 0.76
Absence of linkage or association for osteoarthritis with the vitamin D receptor/type II collagen locus: the Framingham Osteoarthritis Study. J Rheumatol (2002) 0.76
Comparative multi-goal tradeoffs in systems engineering of microbial metabolism. BMC Syst Biol (2012) 0.75
Correction: RNA Sequence Analysis of Human Huntington Disease Brain Reveals an Extensive Increase in Inflammatory and Developmental Gene Expression. PLoS One (2016) 0.75
Decreased parvalbumin mRNA expression in dorsolateral prefrontal cortex in Parkinson's disease. Brain Res (2013) 0.75
The association of cell cycle checkpoint 2 variants and kidney function: findings of the Family Blood Pressure Program and the Atherosclerosis Risk In Communities study. Am J Hypertens (2009) 0.75